Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EU Exclusivity Review: Commission To Assess Impact On 'Skyrocketing' Drug Prices

This article was originally published in The Pink Sheet Daily

Executive Summary

Analysis will consider effect of incentives such as data exclusivity and supplementary protection certificates on drug prices, availability and access to medicines; European health ministers also pledge cooperation rein in what they see as the very high prices of some medicines.


Related Content

EU Report Probes Impact Of IP Incentives On R&D, Market Access
Trenches, Silos And Circular Debates: European Health Forum Calls For Collaboration On IP And Medicines Access
Busy In-Tray Awaits New EFPIA Boss Nathalie Moll





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts